Showing 801-810 of 1110 results for "".
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- Johnson & Johnson Starts Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/Johnson & Johnson launched a late-stage study of its COVID-19 vaccine candidate JNJ-78436735 following positive interim results from a phase 1/2a trial. The ENSEMBLE study will enroll up to 60,000 volunteers and will evaluate the safety and efficacy of a single vaccine dose versus placebo in
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo
- Why Johnson & Johnson is Investing in This Niche Telehealth Startuphttps://modernod.com/news/why-johnson-johnson-is-investing-in-this-niche-telehealth-startup/2478171/Pharmaceutical giant Johnson & Johnson is investing in direct-to-consumer telehealth company Thirty Madison. New York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux, according to a FierceHealthcare
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont
- Johnson & Johnson Forges $1-Billion Pact to Supply US with COVID-19 Vaccinehttps://modernod.com/news/johnson-johnson-forges-1-billion-pact-to-supply-us-with-covid-19-vaccine/2478133/Johnson & Johnson said it entered into an agreement with the US government for the large-scale domestic manufacturing and delivery of 100 million doses of its investigational SARS-CoV-2 vaccine Ad26.COV2.S for use in the country. Specifically, the US Biomedical Advanced Research and Developme
- Johnson & Johnson Vision Donates $320K to Support Practitioners and Schools of Optometry Impacted by COVID-19https://modernod.com/news/johnson-johnson-vision-donates-320k-to-support-practitioners-and-schools-of-optometry-impacted-by-covid-19/2477924/As part of ongoing initiatives to help support eye care in the wake of COVID-19, Johnson & Johnson Vision announced donations to Optometry Cares, the charitable foundation of The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation (AAOF). A
- Johnson & Johnson Vision Presents Myopia Research Findings at ARVOhttps://modernod.com/news/johnson-johnson-vision-presents-myopia-research-findings-reports-contact-lens-iol-and-equipment-data-at-arvo-annual-meeting/2479519/Johnson & Johnson Vision will present the first clinical research findings from its comprehensive myopia clinical research program with the Singapore Eye Research Institute (SERI) and Singapore National Eye Centre (SNEC), as well as new data on contact lens and surgical innovations, at the 20
- Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate/2477889/Johnson & Johnson announced that through its Janssen Pharmaceutical Companies division that it has accelerated the initiation of the phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the tri